| nadroparin vs placebo | No demonstrated result Major bleeding by 151% (harmful effect) suggested Symptomatic venous thromboembolism (DVT, PE) by 71% (not demonstrated) suggested wound haematoma / infection by 88% (not demonstrated) suggested transfusion by 65% (not demonstrated) suggested Bleeding by 109% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic pulmonary embolism | 0.25 [0.05 1.18] | p=1.00 | 0 | 4498 | 1 | Pezzuoli, | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | 0.29 [0.11 0.80] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | wound haematoma / infection | 1.88 [1.52 2.33] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | transfusion | 1.65 [1.32 2.07] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | Bleeding | 2.09 [1.76 2.50] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | Major bleeding | 2.51 [1.89 3.34] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | All cause death | 0.45 [0.19 1.03] | p=1.00 | 0 | 4498 | 1 | Pezzuoli, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
